Precigen narrows focus and cuts workforce

8 August 2024

US cell and gene therapy company Precigen (Nasdaq: PGEN) has announced a strategic reprioritization of the company's clinical portfolio and streamlining of resources.

There will be a reduction of more than 20% of the company’s workforce, to focus on potential commercialization of the PRGN-2012 AdenoVerse gene therapy for the treatment of recurrent respiratory papillomatosis (RRP).

According to Precigen, these strategic changes substantially reduce required resources for non-priority programs and will enable the company to focus on pre-commercialization efforts on PRGN-2012.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK